Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Arizona.
Press releases published on July 23, 2025
Stereotaxis to Report Second Quarter 2025 Financial Results on August 7, 2025
GlobeNewswire
·
July 23, 2025
ST. LOUIS, July 23, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 second quarter on …
High Quality, Increased Member Satisfaction, Better Access to Care and Improved Outcomes Highlight Alignment Healthcare’s Impact in 2024
GlobeNewswire
·
July 23, 2025
ORANGE, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) today released its 2024 Impact Report outlining how it continued to deliver high-quality, personalized care to seniors while creating a positive impact on its …
IMUNON Announces Reverse Stock Split
GlobeNewswire
·
July 23, 2025
LAWRENCEVILLE, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced a reverse stock split of its issued and outstanding common stock, par …
electroCore to Announce Second Quarter June 30, 2025 Financial Results on Wednesday, August 6, 2025
GlobeNewswire
·
July 23, 2025
ROCKAWAY, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the second quarter ended June 30, 2025, after the …
Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
GlobeNewswire
·
July 23, 2025
- SGT-501 has now received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations - - Potential first-in-class therapy with FDA IND clearance and Health Canada CTA approval designed to address underlying causes of CPVT, a life-threatening, …
PetMeds Partners with myBalto Foundation to Raise Nearly $45,000 to Alleviate Financial Stress Pet Owners Face with Emergency Vet Bills
GlobeNewswire
·
July 23, 2025
DELRAY BEACH, Fla., July 23, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (“PetMeds®”) (NASDAQ: PETS) today announced that it partnered with the myBalto Foundation for its recent “Top of the Class” fundraising drive, resulting in nearly $45,000 in …
Ambulatory Surgery Center Completes WATER IV Trial Procedures for Prostate Cancer with Aquablation® Therapy
GlobeNewswire
·
July 23, 2025
SAN JOSE, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through transformative urology solutions, today announced that three …
Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness
GlobeNewswire
·
July 23, 2025
Collaboration aims to accelerate development of OPGx-RDH12, a gene therapy for RDH12-associated Leber congenital amaurosis (RDH12-LCA) RESEARCH TRIANGLE PARK, N.C., July 23, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage …
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
GlobeNewswire
·
July 23, 2025
THE WOODLANDS, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2025 financial results on Wednesday, August 6, 2025, prior to market open. Management will …
Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science
GlobeNewswire
·
July 23, 2025
Transforming a promising molecule into a clinically viable therapeutic platform Jupiter, Florida, July 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing …
Humacyte Announces First Symvess™ Sale to Military Treatment Facility
GlobeNewswire
·
July 23, 2025
Sale follows recent Electronic Catalog (ECAT) listing approval by U.S. Defense Logistics Agency Symvess now available to U.S. Department of Defense and U.S. Department of Veterans Affairs facilities DURHAM, N.C., July 23, 2025 (GLOBE NEWSWIRE) -- Humacyte, …
Respiree Closes US$11.6M Series A Financing Round Led by We Venture Capital and ClavystBio
GlobeNewswire
·
July 23, 2025
HOUSTON and SINGAPORE, July 23, 2025 (GLOBE NEWSWIRE) -- Respiree, a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the healthcare continuum, announced the successful closing of a US$11.6 million …
Quanta Announces Leadership Team Appointment and Highlights Clinical Program Progress
GlobeNewswire
·
July 23, 2025
– 25-year industry veteran Vanessa L. Jacoby appointed CBO and CFO, bringing financial and strategic leadership – – Enrollment initiated in dose expansion cohorts in Phase 1 clinical trial of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in …
Ascentage Pharma to Participate in BTIG Virtual Biotechnology Conference 2025
GlobeNewswire
·
July 23, 2025
ROCKVILLE, Md. and SUZHOU, China, July 23, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in …
Belite Bio to Participate in the BTIG Virtual Biotechnology Conference
GlobeNewswire
·
July 23, 2025
SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today …
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib
GlobeNewswire
·
July 23, 2025
Breakthrough Therapy Designation granted to elironrasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received prior chemotherapy and immunotherapy but have not been previously …
Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs
GlobeNewswire
·
July 23, 2025
During the year ended April 30, 2025, net cash provided by financing activities was $10.4 million Stockholder equity of $4.0 million at April 30, 2025, including $3.9 million of cash In May 2025, Alzamend dosed the first patient for the healthy human …
Regen BioPharma, Inc. to Seek Orphan Drug Designation for Lead Product
GlobeNewswire
·
July 23, 2025
An Orphan Drug Designation Could Provide Significant Benefits to Regen SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC Pink: RGBP and RGBPP) today provides further insight into its planned Phase 1 clinical trial of HemaXellerate, …
ProPhase Labs Announces Closing of $3 Million Senior Secured Convertible Notes Financing
GlobeNewswire
·
July 23, 2025
Financing provides bridge to multiple potentially significant liquidity events and crypto strategies UNIONDALE, NY, July 23, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), (the "Company" or "ProPhase") today announced the closing of a private …
Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025
GlobeNewswire
·
July 23, 2025
DUBLIN and BRIDGEWATER, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President …